ARS Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
ARS Pharmaceuticals, Inc. (SPRY) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 4.27 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 578.90K shares, a 12.56% increase year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 3.70M shares, a 39.76% increase year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 68.10K shares, a 92.36% decline year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 137.60K shares, a 86.16% decline year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 3.36M shares, a 36.71% decline from fiscal 2024.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 5.32M shares, a 11.91% increase from fiscal 2023.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 4.75M shares, a 222.52% increase from fiscal 2022.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.47M shares, a 187.75% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 578.90K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 4.27M shares 10-Q · filed 2026-08-13 | 4.34M shares derived: sum of 3 quarters · filed 2026-08-13 | 4.48M shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 3.70M shares 10-Q · filed 2026-05-15 | 3.76M shares derived: sum of 2 quarters · filed 2026-05-15 | 3.90M shares derived: sum of 3 quarters · filed 2026-05-15 | 4.42M shares derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | 68.10K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 205.70K shares derived: sum of 2 quarters · filed 2026-03-09 | 720.00K shares derived: sum of 3 quarters · filed 2026-03-09 | 3.36M shares 10-K · filed 2026-03-09 |
| 2025-09-30 | 137.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 651.90K shares derived: sum of 2 quarters · filed 2025-11-10 | 3.30M shares 10-Q · filed 2025-11-10 | 4.19M shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 514.30K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | 3.16M shares 10-Q · filed 2025-08-13 | 4.05M shares derived: sum of 3 quarters · filed 2025-08-13 | 5.04M shares derived: sum of 4 quarters · filed 2025-08-13 |
| 2025-03-31 | 2.64M shares 10-Q · filed 2025-05-14 | 3.54M shares derived: sum of 2 quarters · filed 2025-05-14 | 4.53M shares derived: sum of 3 quarters · filed 2025-05-14 | 4.89M shares derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-12-31 | 891.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 1.89M shares derived: sum of 2 quarters · filed 2025-03-20 | 2.25M shares derived: sum of 3 quarters · filed 2025-03-20 | 5.32M shares 10-K · filed 2025-03-20 |
| 2024-09-30 | 994.20K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 1.35M shares derived: sum of 2 quarters · filed 2024-11-13 | 4.42M shares 10-Q · filed 2024-11-13 | 4.42M shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 360.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 3.43M shares 10-Q · filed 2024-08-06 | 3.43M shares derived: sum of 3 quarters · filed 2024-08-06 | 3.43M shares derived: sum of 4 quarters · filed 2024-08-06 |
| 2024-03-31 | 3.07M shares 10-Q · filed 2024-05-09 | 3.07M shares derived: sum of 2 quarters · filed 2024-05-09 | 3.07M shares derived: sum of 3 quarters · filed 2024-05-09 | 3.72M shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 0.00 shares derived: sum of 2 quarters · filed 2024-03-21 | 650.00K shares derived: sum of 3 quarters · filed 2024-03-21 | 4.75M shares 10-K · filed 2024-03-21 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 650.00K shares derived: sum of 2 quarters · filed 2023-11-09 | 4.75M shares 10-Q · filed 2023-11-09 | 3.13M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 650.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 4.75M shares 10-Q · filed 2023-08-10 | 3.13M shares derived: sum of 3 quarters · filed 2023-08-10 | 3.13M shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 4.10M shares 10-Q · filed 2023-05-15 | 2.48M shares derived: sum of 2 quarters · filed 2023-05-15 | 2.48M shares derived: sum of 3 quarters · filed 2023-05-15 | 3.74M shares derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-12-31 | -1.62M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -1.62M shares derived: sum of 2 quarters · filed 2023-03-23 | -360.08K shares derived: sum of 3 quarters · filed 2023-03-23 | 1.47M shares 10-K · filed 2023-03-23 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | 1.26M shares derived: sum of 2 quarters · filed 2022-11-02 | 3.09M shares 10-Q · filed 2022-11-02 | 3.16M shares derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-06-30 | 1.26M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 3.09M shares 10-Q · filed 2022-08-11 | 3.16M shares derived: sum of 3 quarters · filed 2022-08-11 | 3.27M shares derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | 1.83M shares 10-Q · filed 2022-05-12 | 1.91M shares derived: sum of 2 quarters · filed 2022-05-12 | 2.02M shares derived: sum of 3 quarters · filed 2022-05-12 | 2.25M shares derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-12-31 | 75.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | 182.90K shares derived: sum of 2 quarters · filed 2022-03-31 | 417.80K shares derived: sum of 3 quarters · filed 2022-03-31 | 511.77K shares 10-K · filed 2022-03-31 |
| 2021-09-30 | 107.90K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 342.80K shares derived: sum of 2 quarters · filed 2021-11-10 | 436.77K shares 10-Q · filed 2021-11-10 | |
| 2021-06-30 | 234.90K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | 328.87K shares 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | 93.97K shares 10-Q · filed 2021-05-13 | |||
| 2020-03-31 | 0.00 shares 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |